648 related articles for article (PubMed ID: 28982863)
1. Effects of ADAM10 and ADAM17 Inhibitors on Natural Killer Cell Expansion and Antibody-dependent Cellular Cytotoxicity Against Breast Cancer Cells
Pham DH; Kim JS; Kim SK; Shin DJ; Uong NT; Hyun H; Yoon MS; Kang SJ; Ryu YJ; Cho JS; Yoon JH; Lee JS; Cho D; Lee SH; Park MH
Anticancer Res; 2017 Oct; 37(10):5507-5513. PubMed ID: 28982863
[TBL] [Abstract][Full Text] [Related]
2. The inhibition of ADAM17 in cord blood stem cell-derived CD16
Valipour B; Mohammadi SM; Abedelahi A; Charoudeh HN
Hum Immunol; 2024 May; 85(3):110769. PubMed ID: 38429146
[TBL] [Abstract][Full Text] [Related]
3. Hepatitis C virus-induced NK cell activation causes metzincin-mediated CD16 cleavage and impaired antibody-dependent cytotoxicity.
Oliviero B; Mantovani S; Varchetta S; Mele D; Grossi G; Ludovisi S; Nuti E; Rossello A; Mondelli MU
J Hepatol; 2017 Jun; 66(6):1130-1137. PubMed ID: 28192188
[TBL] [Abstract][Full Text] [Related]
4. Taxanes enhance trastuzumab-mediated ADCC on tumor cells through NKG2D-mediated NK cell recognition.
Di Modica M; Sfondrini L; Regondi V; Varchetta S; Oliviero B; Mariani G; Bianchi GV; Generali D; Balsari A; Triulzi T; Tagliabue E
Oncotarget; 2016 Jan; 7(1):255-65. PubMed ID: 26595802
[TBL] [Abstract][Full Text] [Related]
5. Shedding of endogenous MHC class I-related chain molecules A and B from different human tumor entities: heterogeneous involvement of the "a disintegrin and metalloproteases" 10 and 17.
Chitadze G; Lettau M; Bhat J; Wesch D; Steinle A; Fürst D; Mytilineos J; Kalthoff H; Janssen O; Oberg HH; Kabelitz D
Int J Cancer; 2013 Oct; 133(7):1557-66. PubMed ID: 23526433
[TBL] [Abstract][Full Text] [Related]
6. V gamma 9 V delta 2 T cell cytotoxicity against tumor cells is enhanced by monoclonal antibody drugs--rituximab and trastuzumab.
Tokuyama H; Hagi T; Mattarollo SR; Morley J; Wang Q; So HF; Moriyasu F; Nieda M; Nicol AJ
Int J Cancer; 2008 Jun; 122(11):2526-34. PubMed ID: 18307255
[TBL] [Abstract][Full Text] [Related]
7. IL-15 and IL-2 increase Cetuximab-mediated cellular cytotoxicity against triple negative breast cancer cell lines expressing EGFR.
Roberti MP; Barrio MM; Bravo AI; Rocca YS; Arriaga JM; Bianchini M; Mordoh J; Levy EM
Breast Cancer Res Treat; 2011 Nov; 130(2):465-75. PubMed ID: 21308409
[TBL] [Abstract][Full Text] [Related]
8. Synthesis and in vitro Evaluation of ADAM10 and ADAM17 Highly Selective Bioimaging Probes.
Camodeca C; Nuti E; Tosetti F; Poggi A; D'Arrigo C; Zocchi MR; Rossello A
ChemMedChem; 2018 Oct; 13(19):2119-2131. PubMed ID: 30102846
[TBL] [Abstract][Full Text] [Related]
9. Paclitaxel enhances antibody-dependent cell-mediated cytotoxicity of trastuzumab by rapid recruitment of natural killer cells in HER2-positive breast cancer.
Miura D; Yoneyama K; Furuhata Y; Shimizu K
J Nippon Med Sch; 2014; 81(4):211-20. PubMed ID: 25186575
[TBL] [Abstract][Full Text] [Related]
10. Interleukin-2 enhances the natural killer cell response to Herceptin-coated Her2/neu-positive breast cancer cells.
Carson WE; Parihar R; Lindemann MJ; Personeni N; Dierksheide J; Meropol NJ; Baselga J; Caligiuri MA
Eur J Immunol; 2001 Oct; 31(10):3016-25. PubMed ID: 11592078
[TBL] [Abstract][Full Text] [Related]
11. Natural killer cell cytotoxicity of breast cancer targets is enhanced by two distinct mechanisms of antibody-dependent cellular cytotoxicity against LFA-3 and HER2/neu.
Cooley S; Burns LJ; Repka T; Miller JS
Exp Hematol; 1999 Oct; 27(10):1533-41. PubMed ID: 10517495
[TBL] [Abstract][Full Text] [Related]
12. Long-term preservation of antibody-dependent cellular cytotoxicity (ADCC) of natural killer cells amplified in vitro from the peripheral blood of breast cancer patients after chemotherapy.
Clémenceau B; Gallot G; Vivien R; Gaschet J; Campone M; Vié H
J Immunother; 2006; 29(1):53-60. PubMed ID: 16365600
[TBL] [Abstract][Full Text] [Related]
13. NK cell CD16 surface expression and function is regulated by a disintegrin and metalloprotease-17 (ADAM17).
Romee R; Foley B; Lenvik T; Wang Y; Zhang B; Ankarlo D; Luo X; Cooley S; Verneris M; Walcheck B; Miller J
Blood; 2013 May; 121(18):3599-608. PubMed ID: 23487023
[TBL] [Abstract][Full Text] [Related]
14. Role of ADAM10 and ADAM17 in CD16b shedding mediated by different stimulators.
Guo S; Peng M; Zhao Q; Zhang W
Chin Med Sci J; 2012 Jun; 27(2):73-9. PubMed ID: 22770404
[TBL] [Abstract][Full Text] [Related]
15. Targeting natural killer cells to acute myeloid leukemia in vitro with a CD16 x 33 bispecific killer cell engager and ADAM17 inhibition.
Wiernik A; Foley B; Zhang B; Verneris MR; Warlick E; Gleason MK; Ross JA; Luo X; Weisdorf DJ; Walcheck B; Vallera DA; Miller JS
Clin Cancer Res; 2013 Jul; 19(14):3844-55. PubMed ID: 23690482
[TBL] [Abstract][Full Text] [Related]
16. Matrix metalloproteinases inhibition promotes the polyfunctionality of human natural killer cells in therapeutic antibody-based anti-tumour immunotherapy.
Zhou Q; Gil-Krzewska A; Peruzzi G; Borrego F
Clin Exp Immunol; 2013 Jul; 173(1):131-9. PubMed ID: 23607800
[TBL] [Abstract][Full Text] [Related]
17. ADAM10 mediates trastuzumab resistance and is correlated with survival in HER2 positive breast cancer.
Feldinger K; Generali D; Kramer-Marek G; Gijsen M; Ng TB; Wong JH; Strina C; Cappelletti M; Andreis D; Li JL; Bridges E; Turley H; Leek R; Roxanis I; Capala J; Murphy G; Harris AL; Kong A
Oncotarget; 2014 Aug; 5(16):6633-46. PubMed ID: 24952873
[TBL] [Abstract][Full Text] [Related]
18. Anticancer chemotherapy inhibits MHC class I-related chain a ectodomain shedding by downregulating ADAM10 expression in hepatocellular carcinoma.
Kohga K; Takehara T; Tatsumi T; Miyagi T; Ishida H; Ohkawa K; Kanto T; Hiramatsu N; Hayashi N
Cancer Res; 2009 Oct; 69(20):8050-7. PubMed ID: 19826051
[TBL] [Abstract][Full Text] [Related]
19. Metalloprotease-mediated tumor cell shedding of B7-H6, the ligand of the natural killer cell-activating receptor NKp30.
Schlecker E; Fiegler N; Arnold A; Altevogt P; Rose-John S; Moldenhauer G; Sucker A; Paschen A; von Strandmann EP; Textor S; Cerwenka A
Cancer Res; 2014 Jul; 74(13):3429-40. PubMed ID: 24780758
[TBL] [Abstract][Full Text] [Related]
20. Effects of HER Family-targeting Tyrosine Kinase Inhibitors on Antibody-dependent Cell-mediated Cytotoxicity in HER2-expressing Breast Cancer.
Collins DM; Madden SF; Gaynor N; AlSultan D; Le Gal M; Eustace AJ; Gately KA; Hughes C; Davies AM; Mahgoub T; Ballot J; Toomey S; O'Connor DP; Gallagher WM; Holmes FA; Espina V; Liotta L; Hennessy BT; O'Byrne KJ; Hasmann M; Bossenmaier B; O'Donovan N; Crown J
Clin Cancer Res; 2021 Feb; 27(3):807-818. PubMed ID: 33122343
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
